PAVmed to license esophageal imaging technology from Duke Technology

PAVmed (PAVM) has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke’s technology to identify and facilitate treatment of advanced esophageal precancer – dysplasia – during upper endoscopy. This technology-a multi-modality probe combining angle-resolved low coherence interferometry with optical coherence tomography – could allow for a more efficient and effective alternative to traditional biopsies. Prior clinical research performed by Dr. Shaheen and Dr. Wax has shown that a/LCI can accurately detect precancerous changes in the esophagus during live examinations with 100% sensitivity and overall accuracy of 88% when used alone. PAVmed, through the newly-formed subsidiary, will enter into a definitive license agreement for the exclusive worldwide license of the intellectual property rights for the a/LCI + OCT technology. The proposed license will not be become effective unless and until a definitive license agreement has been executed by all parties.